VBI Vaccines Insiders
VBI Vaccines employs about 131 people. The company is managed by 12 executives with a total tenure of roughly 20 years, averaging almost 1.0 years of service per executive, having 10.92 employees per reported executive. Recap of VBI Vaccines' management performance can provide insight into the venture performance.
Adam Buckley President Vice President - Operations and Project Management |
Athena Kartsaklis President Principal Financial and Accounting Officer, Senior Vice President - Finance, Chief Compliance Officer, Corporate Controller |
VBI |
VBI Vaccines Management Team Effectiveness
The company has return on total asset (ROA) of (0.2915) % which means that it has lost $0.2915 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (4.1959) %, meaning that it created substantial loss on money invested by shareholders. VBI Vaccines' management efficiency ratios could be used to measure how well VBI Vaccines manages its routine affairs as well as how well it operates its assets and liabilities.VBI Vaccines Workforce Comparison
VBI Vaccines is rated below average in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 2,433. VBI Vaccines holds roughly 131 in number of employees claiming about 5% of equities under Health Care industry.
VBI Vaccines Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific VBI Vaccines insiders, such as employees or executives, is commonly permitted as long as it does not rely on VBI Vaccines' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, VBI Vaccines insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Diaz-mitoma Francisco over three months ago Acquisition by Diaz-mitoma Francisco of 40000 shares of VBI Vaccines at 0.5 subject to Rule 16b-3 | ||
Avi Mazaltov over a year ago Acquisition by Avi Mazaltov of 52500 shares of VBI Vaccines subject to Rule 16b-3 | ||
Perceptive Advisors Llc over a year ago Sale by Perceptive Advisors Llc of 4810623 shares of VBI Vaccines | ||
Steven Gillis over a year ago Acquisition by Steven Gillis of 75000 shares of VBI Vaccines subject to Rule 16b-3 |
VBI Vaccines Notable Stakeholders
A VBI Vaccines stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as VBI Vaccines often face trade-offs trying to please all of them. VBI Vaccines' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting VBI Vaccines' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Jeffery FCMA | CEO President | Profile | |
Adam Buckley | Vice President - Operations and Project Management | Profile | |
Athena Kartsaklis | Principal Financial and Accounting Officer, Senior Vice President - Finance, Chief Compliance Officer, Corporate Controller | Profile | |
Christopher McNulty | CFO and Head of Business Development | Profile | |
FRCPC MD | Chief Officer | Profile | |
FCMA FCMA | CEO Pres | Profile | |
Nicole Anderson | Director Relations | Profile | |
Avi Mazaltov | Global SciVac | Profile | |
Misha Nossov | Senior Europe | Profile | |
David Anderson | Chief Scientific Officer | Profile | |
Nell Beattie | Chief Officer | Profile | |
John Dillman | Chief Officer | Profile |
About VBI Vaccines Management Performance
The success or failure of an entity such as VBI Vaccines often depends on how effective the management is. VBI Vaccines management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of VBI management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the VBI management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts. Vbi Vaccines operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 149 people.
Please note, the imprecision that can be found in VBI Vaccines' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of VBI Vaccines. Check VBI Vaccines' Beneish M Score to see the likelihood of VBI Vaccines' management manipulating its earnings.
VBI Vaccines Workforce Analysis
Traditionally, organizations such as VBI Vaccines use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare VBI Vaccines within its industry.VBI Vaccines Manpower Efficiency
Return on VBI Vaccines Manpower
Revenue Per Employee | 66.3K | |
Revenue Per Executive | 723.5K | |
Net Loss Per Employee | 708.7K | |
Net Loss Per Executive | 7.7M |
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Consideration for investing in VBI Stock
If you are still planning to invest in VBI Vaccines check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the VBI Vaccines' history and understand the potential risks before investing.
Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Content Syndication Quickly integrate customizable finance content to your own investment portal |